Optimizing the management of hepatobiliary neoplasms: a multidisciplinary and molecular challenge

Hepatobiliary neoplasms represent a group of common, biologically and clinically diverse diseases. Hepatocellular carcinoma (HCC) is the second leading cause of death in men worldwide with less than 20% 5-year survival rates (1). Less common biliary tract cancers, including intra- and extrahepatic cholangiocarcinoma and cancers of the gallbladder, are likewise associated with poor long-term survival. Late stage at diagnosis, underlying liver dysfunction, and the lack of highly active systemic therapies represent the major challenges driving these historical outcomes. Technological advances in locoregional modalities and major strides in understanding the molecular pathogenesis of these cancers herald a new era of therapeutic opportunities. In this special issue of Journal of Gastrointestinal Oncology (JGO) , a variety of comprehensive reviews highlight the multidisciplinary advancements and efforts required for optimizing care for patients with hepatobiliary neoplasms.